RxDoctor Payments Data

Troy Randle, DO

Cardiovascular Disease · Cherry Hill, NJNPI 1710187513

Payments from drug & device makers

$38,371in general payments, 2019–2025

Across 867 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$24K
  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Atricure, Inc.$1K
  • Irhythm Technologies, Inc.$1K
  • Novartis$1K
  • plus $8K from 26 others

What the payments were for

  • Speaking & faculty fees$19,06350%
  • Travel & lodging$1,0253%
  • Food & beverage$18,26248%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,371 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$150,470
Medicare patients
597
Services billed
1,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban536$539,921
EntrestoSacubitril/Valsartan199$185,158
XareltoRivaroxaban100$108,661
JardianceEmpagliflozin133$106,837
FarxigaDapagliflozin Propanediol120$105,583
Repatha SureclickEvolocumab128$96,969
BrilintaTicagrelor49$27,210
WegovySemaglutide12$17,700
OzempicSemaglutide15$15,009
Atorvastatin Calcium1,224$12,432
Metoprolol Succinate854$10,530
Praluent PenAlirocumab19$9,340
CorlanorIvabradine Hcl14$8,744
Losartan Potassium881$6,771
Rosuvastatin Calcium396$6,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$585$539,921536 claims
NovartisEntresto$1,120$185,158199 claims
AstraZenecaFarxiga, Brilinta$608$132,794169 claims
Johnson & JohnsonXarelto$532$108,661100 claims
Boehringer IngelheimJardiance$648$106,837133 claims
Novo NordiskWegovy, Ozempic$218$32,70927 claims
AmgenCorlanor$775$8,74414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →